In my opinion, there appears to be two material issues with BDSI:
1. The pipeline has been valued at zero now because there are huge concerns about the ability of this company to get any non-BEMA product approved. The track record supports this valuation and frankly I think they need to take a long hard look at what they have acquired before moving forward. I certainly wouldn't move forward with Finn managing the development. The CTG trial seems to be a complete cluster. Following the cluster on Bunevail. Seems they need to figure the problem out quickly or Wall Street will pass them off as a one trick pony which can't manage studies.
2. Surprisingly the second problem magnifies the first. Despite what I believe to be a struggle with non BEMA R&D they don't have enough R&D going to be able to weather the storm of a failure. They are managing costs which is great but they need to feed the Wall Street beast. If practical, I would get multiple BEMA products in development asap so they can have other opportunities for investors to look to if one fails. Given the problem with 1, this is a catch 22. With Finn approaching 70, and a spotty track record at this time, they're in a bit of a bind.
Wouldn't hurt for management to attempt to assure the market that CTG is a hiccup in the life of BDSI and that the selloff is overdone. Assuming they believe this.